Neuronetics Launches New Website to Meet Patient Demand for Depression Resources

Neuronetics, Inc

MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) announced its new website to meet consumer demand for information on accessing advanced treatments for depression. The enhanced site also makes it easier for healthcare providers to learn more about this important treatment option for their patients. NeuroStar Advanced Therapy for Mental Health is the leading non-drug and non-invasive transcranial magnetic stimulation (TMS) treatment for depression.

In a recent market research survey commissioned by Neuronetics, 67 percent of patients with Major Depressive Disorder (MDD) said they were unhappy with their current treatment; 60 percent wish there were better options; and 56 percent were extremely interested in learning about new treatment options for depression – underscoring the critical need for more mental health resources and awareness on available non-drug alternatives. Aligning with this research, the Company’s updated website now has added content in a centralized hub to reflect what patients need to make informed decisions about treating depression.

“We are a company that cares about getting people well and transforming lives,” said Keith J. Sullivan, President and CEO of Neuronetics. “As we face a mental health pandemic on the heels of the COVID-19 pandemic, it is more important than ever to arm patients and providers with the resources they need to overcome depression – especially since we know many patients are unhappy with their current treatments and open to new options like NeuroStar. Enhancing the user experience and revamping our website to highlight reliable, need-to-know information about NeuroStar as an available treatment is one of the many ways we are making it easier for people to tackle depression.”

READ:  Baudax Bio Announces Distribution of Series B Preferred Stock to Holders of Its Common Stock

In addition to a seamless, improved user experience and easier navigation, the redesigned website further advances key conversations around depression and includes:

  • Depression-related content for individuals to determine whether NeuroStar Advanced Therapy for Mental Health could be a treatment to consider
  • Updated physician locator tool to help prospective patients find a NeuroStar provider by distance, free consultation availability or Stellar Distinctions designation based on the number of patients treated
  • New NeuroStar patient and provider success stories highlighting the in-office experience and depression relief possible for patients treated with NeuroStar

As the TMS market leader, Neuronetics understands the patient journey and continues to innovate its educational materials to help those with depression who haven’t had success with antidepressant medications. The patient insights research coupled with rising depression rates – with four in ten adults in the US reporting symptoms of depression or anxiety connected to the COVID-19 pandemic1 – validates Neuronetics’ important commitment to transform lives and address an unmet need for patients.

The website is designed to encourage open dialogue around mental health and connect patients, caregivers and others with doctors directly. The site will be updated with new resources as they become available. To learn more, visit www.neurostar.com.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.

Thanks for visiting! Looking for some Chester County pride? We got you covered! Shop our MyChesCo store and show your love for Chester County, Pennsylvania. We got shirts, hats, and more – all with a unique ChesCo flair. Plus, proceeds from each purchase helps support our mission of bringing reliable information and resources to the people of Chester County.